11/18/2025 1 Making the Invisible Visible Q4 FY25 Earnings Presentation November 18, 2025 While forward-looking statements are based on assumptions and analyses made by management of Varex that it believes to be reasonable under the circumstances, whether actual results and developments will meet such expectations depends on a number of risks and uncertainties which could cause actual results, performance, and financial condition to differ materially from such expectations. Such risks and uncertainties incl ...

Core Insights - FUJIFILM Healthcare Americas Corporation has launched Synapse One, a comprehensive workflow solution tailored for outpatient imaging needs in North America [1] Group 1 - Synapse One is an all-inclusive enterprise imaging solution that addresses various aspects of outpatient imaging [1] - The solution includes features such as a patient engagement portal, self-scheduling of exams, and a Radiology Information System (RIS) [1] - Advanced scheduling capabilities are also part of the Synapse One offering [1]

Core Insights - Positron Corporation has become a reporting company with the U.S. Securities and Exchange Commission (SEC), marking a significant milestone in its growth trajectory [1][2] - The transition to SEC reporting enhances financial transparency, strengthens corporate governance, and positions the company for broader institutional visibility as it plans to uplist to a senior exchange [2] Company Developments - The CEO of Positron Corporation, Adel Abdullah, emphasized the commitment to transparency and high standards of accountability as the company expands its commercialization of PET-CT technologies, including a new 4D PET-CT system [3] - The enhanced reporting status coincides with increasing demand for PET-CT imaging in cardiology and oncology, positioning the company to capture significant market share [3][6] Market Position and Strategy - Positron specializes in cardiac Positron Emission Tomography (PET) imaging, which is considered the gold standard in cardiac diagnostics, and aims to improve patient outcomes while maintaining cost-effective practices [5] - The company’s PET-CT systems are expected to facilitate the adoption of cardiac PET and support the growth of the nuclear imaging market, particularly in oncology [6][7] - Positron is committed to advancing its technology through partnerships, including a co-development venture with Shenyang Intelligent Nuclear Technology Co., a subsidiary of Neusoft Medical Systems [7]

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, and American Molecular Imaging (AMI), one of the leading radiology reading services providers in the U.S., are pleased to announce that they have entered into a strategic business and investment agreement (the “Agreement”), with the ...

Olympe Imagerie to deploy Nanox.ARC at Paris-area Hospital Privé Jacques Cartier MASSY for lung cancer screening applications PETACH TIKVA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced a collaboration with Olympe Imagerie, a Paris-based group of independent radiologists, to deploy the Nanox.ARC and expand its clinical research evidence generation program in France. The Nanox.ARC system ...

Core Insights - Nanox Imaging Ltd will showcase its Nanox.ARC X multi-source digital tomosynthesis system and AI solutions at the RSNA 2025 Annual Meeting from November 30 to December 4, 2025 [1][2] Product Overview - The Nanox.ARC X system, which received FDA 510(k) clearance in April 2025, enables advanced 3D imaging at lower costs and radiation doses compared to CT scans, applicable for various medical indications [2][4] - Live demonstrations of the Nanox.ARC X will occur every 30 minutes at RSNA booth 3914, along with clinical data presentations supporting digital tomosynthesis [3][6] AI Innovations - Nanox is developing a pulmonary nodule AI solution as part of the Nanox.ARC X, along with two standalone AI innovations for measuring aortic valve calcification and body composition [3][4] - The company aims to leverage AI to enhance routine medical imaging efficiency and improve early detection of chronic conditions [9] Event Details - Presentations at RSNA include a focus on AI and digital tomosynthesis in pulmonary nodule detection and applications in the musculoskeletal system [5][6] - A cocktail event discussing the future of radiology and AI will be hosted by Dr. Lawrence Tanenbaum on December 1, 2025 [6][7] Company Vision - Nanox's vision is to expand its technology's reach beyond hospital settings, providing a comprehensive solution from scan to diagnosis, enhancing health outcomes through early detection and treatment [9]

Group 1: Company Performance Overview - Agfa-Gevaert Group reported a continued decline in medical film markets, while experiencing strong growth in cloud and SaaS within HealthCare IT [2][4] - The overall revenue for Q3 2025 decreased by 7.1% to €257 million compared to Q3 2024, with a notable decline in the Radiology Solutions division [3][7] - Adjusted EBITDA for the group fell to €5 million, a decrease of 65.9% year-over-year, primarily due to the decline in Radiology Solutions [4][7] Group 2: Division-Specific Insights - HealthCare IT revenue decreased by 13.0% to €50 million, with a significant shift towards cloud technology impacting financial performance; however, recurring revenue grew by 0.6% [3][16] - Digital Print & Chemicals division saw a revenue increase of 5.1% to €115 million, driven by Specialty Films & Chemicals, despite unfavorable market conditions [4][17] - Radiology Solutions experienced a 19.4% revenue decline to €74 million, heavily influenced by the ongoing decline in the medical film market, particularly in China [3][18] Group 3: Financial Position and Cash Flow - The company achieved a positive free cash flow of €21 million in Q3, attributed to improvements in working capital and cash inflow from the AgfaPhoto arbitration [4][12] - Net financial debt increased from €37 million in Q4 2024 to €65 million by the end of Q3 2025, indicating a rise in overall debt levels [12][38] - The group’s liquidity headroom was reported at €126.8 million at the end of Q3, well above the minimum covenant requirement [12][12] Group 4: Strategic Initiatives and Future Outlook - Agfa is accelerating and extending its restructuring plans to optimize the cost base of traditional film activities, targeting €50 million in savings [5][24] - The company is exploring redevelopment opportunities for its site in Mortsel, Belgium, to support future growth [5][5] - The outlook for 2025 suggests a slightly negative net cash flow, influenced by outstanding receivables from the sale of the Offset Solutions business [10][10]

Financial Performance & Growth - RadNet's Q3 2025 revenue increased by 13.4% compared to Q3 2024, achieving record quarterly revenue[22] - The company's adjusted EBITDA margin increased by 26 basis points to 16.2%[20] - RadNet has a strong liquidity position with $804.7 million in cash balance and a net debt to adjusted EBITDA leverage ratio of approximately 1.0x[22] - The company anticipates a revenue CAGR of +11% to +13% and a Digital Health revenue CAGR of ~30% from 2025 to 2028[788] Procedural Volume Growth - MRI procedural volume grew by 14.8% in aggregate and 11.5% on a same-center basis[21] - CT procedural volume increased by 9.4% in aggregate and 6.7% on a same-center basis[21] - PET/CT procedural volume experienced a significant increase of 21.1% in aggregate and 14.9% on a same-center basis[21] Technology & Innovation - Deep Learning Reconstruction (DLR) allows for 50-75% faster MRIs while improving image quality[43] - RadNet performs over 2 million mammograms a year, representing 5% of all mammograms in the US[283] - AI-assisted reads found clinically significant prostate cancer in 24% of men when MRI was deemed negative by the radiologist[343] Market Trends & Opportunities - The national imaging market is estimated at $100 billion in 2025[568] - The company's joint venture revenue is projected to reach ~$800 million in 2025, reflecting a CAGR of 19.1% from 2022 to 2025[607] - The company has seen ~18x increase in Cardiac CTA volume from Jan 2020 to October 2025[506]

Core Insights - The article discusses the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article emphasizes that users may face access issues if ad-blockers are enabled, suggesting the need to disable them for a better experience [1]

Core Viewpoint - FONAR Corporation reported its financial results for the first quarter of fiscal 2026, showing a mixed performance with revenue growth but significant declines in income metrics [2][5][8]. Financial Performance - Revenues from the FONAR segment increased by 14% to $2.5 million for the quarter ended September 30, 2025, compared to $2.2 million for the same quarter in 2024 [3]. - Revenues from the Health Management Corporation of America (HMCA) segment rose by 3% to $23.5 million for the quarter ended September 30, 2025, compared to $22.8 million in the same quarter of 2024 [4]. - Total net revenues increased by 4% to $26.0 million for the first fiscal quarter ended September 30, 2025, compared to $25.0 million for the same quarter in 2024 [5][8]. - Selling, general and administrative (S, G & A) expenses surged by 33% to $6.8 million for the quarter ended September 30, 2025, compared to $5.1 million for the same quarter in 2024 [5]. - Total costs and expenses increased by 12% to $22.8 million for the quarter ended September 30, 2025, compared to $20.4 million for the same quarter in 2024 [6]. Income Metrics - Income from operations decreased by 30% to $3.2 million for the quarter ended September 30, 2025, compared to $4.6 million for the same quarter in 2024 [9]. - Consolidated net income fell by 33% to $2.7 million for the quarter ended September 30, 2025, compared to $4.0 million for the same quarter in 2024 [9]. - Diluted net income per common share decreased by 26% to $0.34 for the quarter ended September 30, 2025, compared to $0.46 for the same quarter in 2024 [10]. Cash and Balance Sheet - Cash and cash equivalents decreased by 4% to $54.3 million at September 30, 2025, compared to $56.3 million at June 30, 2025 [8][11]. - Total assets increased to $218.4 million at September 30, 2025, compared to $216.9 million at June 30, 2025 [11]. - Total liabilities were $57.0 million at September 30, 2025, compared to $56.8 million at June 30, 2025 [11][12]. - Total equity increased to $161.4 million at September 30, 2025, compared to $160.1 million at June 30, 2025 [12]. Operational Insights - The HMCA segment managed 44 MRI scanners, with a scan volume of 55,106 in the first quarter of fiscal 2026, which is 3.9% higher than the corresponding quarter of fiscal 2025 [14]. - The company plans to add a second MRI at one of its Stand-Up MRI centers and manage a new MRI center later in the fiscal year [14]. - The company is engaged in negotiations for a potential going private transaction, with a special committee established to consider the proposal [15].